Abstract:Objective To evaluate a strategy of using TF siRNA loaded in a novel external stent prepared by hybrid uhrafine fibrous membrane consisting of PLGA/Chitosan nannoparticles as a therapy for vein graft disease.Methods Hybrid ultrafine fibrous membranes consisting of PLGA/Chitosan nannoparticles were fabricated via a specially designed electrospinning setup. After soaking in chloroform to dissolve PLGA. the amount of chitosan in the hybrid membranes was determined. The water uptake of the hybrid ultrafine fibrous membranes was investigated by incubation in phosphate buffer solution.Right jugular vein-carotid artery interposition grafting models in Spragne-Dawley rats were randomly divided into five groups:Group A(external stent consisting of PLGA/CS-TFsiRNA nanoparticles),Group B(external stent consisting of PLGA/CS.Stealth~(TM) RNAi negative control nanoparticles),Group C(external stent consisting of PLGA/CS blank nanoparticles),Group D(external stent consisting of PLGA),Group E(without perivenous extereal stent).BLOCK-iT~(TM) Fluorescent Oligo was used to confirm its stability and successful transfer into the vein graft wall.The vein grafts were harvested at 1,3,7,14,28 d after operation,respectively.The TF protein expression of vein grafts was analyzed by Westem blot and immunochemistry at 1,3,7 d after operation,respectively.The expression of proliferating cell nuclear antigen(PCNA)was identified by immunochemistry methods. The thickness of neointima at 28 d was calculatod by computer imaging analysis system. Results The PLGA and CS amount in PLGA/Chitosan nannoparticles membranes could be well controlled by adjusting the flow rate for electrospinning of PLGA and chitosan nannoparticles, respectively. Because of the introduction of chitosan,which is a naturally hydrophilic polymer,the hybrid membranes exhibited good water absorption properties.BIOCK-iT~(TM) Fluorescent Oligo could be detected in the graft wall even 12days after operation.The expression of TF protein in Group A Was significantly less than that in control groups at 3 d after operation(P＜0.05,0.40±0.03 vs 0.75 ±0.01、0.75 ±0.05、0.77 ±0.07)and at 7 d after operation(P＜0.05,0.30±0.03 vs 0.84±0.05、0.86±0.06、0.85±0.06).The expression of PCNA in Group A decreased significantly in comparison with control groups at 14 d after operation(P＜0.01,13.0%±2.6%vs 25.0%±2.8%、24.2%±3.9%、24.0%±4.1%、44.8%±3.7%).The thickness of neointima at 28 d after grafting in Group A Was significantly less than the untreated group(P＜0.01,18.8μm±2.9 μm vs 38.7 μm±5.0μm、37.3μm ±3.6 μm、37.2μm±2.6μm、67.5μm±4.8μm).Conclusion rrhe hovel external stent prepared by hybrid uhrafine fibrous membrane consisting of PLGA/Chitosan nannoparticles inhibits early neointima formation in rat vein grafts.This strategy may be a practicable and promising form of gene delivery against vein graft failure.

C-myc antisense oligodeoxynucleotides transferred by soluble stent inhibit the expression of c-myc mRNA

Effect on the Expression of C-myc and Proliferating Cell Nuclear Antigen of Vein Grafts Transferred by C-myc Antisense Oligodeoxynucleotides of Soluble Stent

C-myc antisense oligodeoxynucleotides transferred by soluble stent preventing vein graft stenosis

Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts

Effects of Different Distension Pressures on the Expression of C-Myc and C-Fos Mrna in Rabbit External Jugular Vein Graftss

[The Study on Platelet-Derived Growth Factor and Proliferating Cell Nuclear Antigen Antisense Oligodeoxynucleotides Together Inhibiting the Stenosis of Transplanted Vascular].

Effects of Haemopoietic Stem Cell Mobilization on Improving Vein Graft Patency

Polymer-based Delivering of Shrna to Rabbit Aortic Smooth Muscle Cells Suppressed the Expression of IGF-1R in Vitro and in Vivo.

Gene Transfer of A Broad Spectrum Cc-Chemokine Inhibitor Reduces Vein Graft Atherosclerosis in Apolipoprotein E-Knockout Mice

[Effects of Vascular Endothelial Growth Factor (VEGF) Antisense Oligodeoxynucleotide on Mrna and Expression of VEGF, Flt-1, and Kinase Insert Domain Containing Receptor and VEGF Excretion in Human Gallbladder Carcinoma Cells].

microRNA-18a-5p promotes vascular smooth muscle cell phenotypic switch by targeting Notch2 as therapeutic targets in vein grafts restenosis

Intravascular Magnetic Resonance/radiofrequency May Enhance Gene Therapy for Prevention of In-Stent Neointimal Hyperplasia.

Local Gene Transfer of Tissue Inhibitor of Metalloproteinase-2 Influences Vein Graft Remodeling in a Mouse Model

Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis

A Soft, Conductive External Stent Inhibits Intimal Hyperplasia in Vein Grafts by Electroporation and Mechanical Restriction

Morphologic and Molecular Changes of Autologous Artery Graft Interposed to Vein

Inhibitory effects of local transfection of vascular endothelial growth factor 165 gene on intimal hyperplasia of artery in rabbits after operation injury

The effect of lncRNA MIR155HG-modified MSCs and exosome delivery to synergistically attenuate vein graft intimal hyperplasia

[Effect of Nanoparticle with Vascular Endothelial Growth Factor Gene Transferred into Ischemic Myocardium: Experiment with Rabbits].

Co-transfection of tPA gene and c-myc antisense oligodeoxynucleotides for the prevention of intimal hyperplasia of rabbit auto-transplantion artery

[Inhibition of K562 Cell Growth and Tumor Angiogenesis in Nude Mice by Antisense VEGF(121) Cdna Transfection].